Aurinia Pharmaceuticals (AUPH) Issues Earnings Results

Share on StockTwits

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) announced its earnings results on Thursday. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04), Morningstar.com reports. The company had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.07 million. Aurinia Pharmaceuticals had a negative return on equity of 30.34% and a negative net margin of 12,536.05%.

Shares of AUPH traded up $0.05 during mid-day trading on Friday, hitting $5.65. The company’s stock had a trading volume of 883,496 shares, compared to its average volume of 444,432. Aurinia Pharmaceuticals has a one year low of $4.41 and a one year high of $6.69. The stock has a market capitalization of $476.10 million, a price-to-earnings ratio of -6.14 and a beta of 2.22.

A number of equities research analysts have issued reports on AUPH shares. BidaskClub raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, July 14th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, September 26th. Cantor Fitzgerald set a $18.00 target price on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, August 11th. ValuEngine raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 28th. Finally, Zacks Investment Research cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, October 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $11.79.

Several institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC boosted its position in shares of Aurinia Pharmaceuticals by 2.1% in the third quarter. FMR LLC now owns 4,680,959 shares of the biotechnology company’s stock valued at $31,082,000 after acquiring an additional 95,650 shares during the period. Stanley Laman Group Ltd. bought a new stake in shares of Aurinia Pharmaceuticals in the second quarter valued at approximately $276,000. Ironwood Investment Management LLC boosted its position in shares of Aurinia Pharmaceuticals by 18.0% in the second quarter. Ironwood Investment Management LLC now owns 218,568 shares of the biotechnology company’s stock valued at $1,231,000 after acquiring an additional 33,279 shares during the period. Creative Planning boosted its position in shares of Aurinia Pharmaceuticals by 8.2% in the second quarter. Creative Planning now owns 171,200 shares of the biotechnology company’s stock valued at $964,000 after acquiring an additional 13,000 shares during the period. Finally, Cornerstone Wealth Management LLC bought a new stake in shares of Aurinia Pharmaceuticals in the second quarter valued at approximately $2,000,000. 24.87% of the stock is owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Week Herald and is the sole property of of Week Herald. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://weekherald.com/2018/11/10/aurinia-pharmaceuticals-auph-issues-earnings-results.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Story: Google Finance Portfolio

Earnings History for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply